Anti-CD8 mAb preconditioning but not anti-NK reduces the effective dose of TBI
mAb . | No. animals . | Engraftment, % . | Donor chimerism in PB of engrafted animals, % ± SD . | P compared with TBI alone . |
|---|---|---|---|---|
| None | 10 | 0.0 | NA | NA |
| anti-DX5 | 4 | 0.0 | NA | NS |
| anti-Thy1.2 | 6 | 0.0 | NA | NS |
| anti-CD8 | 9 | 88.9 | 93.6 ± 2.4 | < .001 |
mAb . | No. animals . | Engraftment, % . | Donor chimerism in PB of engrafted animals, % ± SD . | P compared with TBI alone . |
|---|---|---|---|---|
| None | 10 | 0.0 | NA | NA |
| anti-DX5 | 4 | 0.0 | NA | NS |
| anti-Thy1.2 | 6 | 0.0 | NA | NS |
| anti-CD8 | 9 | 88.9 | 93.6 ± 2.4 | < .001 |
NOD mice were treated with the indicated mAb 2 days prior to conditioning with 700 cGy TBI. Allogeneic B10.BR bone marrow cells (BMCs) were subsequently administered, and the mice were monitored for engraftment and chimerism at 28 days. NA indicates not applicable; NS, nonsignificant.